gildeuretinol
Alkeus Pharmaceuticals Appoints Carlos Quezada-Ruiz as Chief Medical Officer
Alkeus Pharmaceuticals; Carlos Quezada-Ruiz; Chief Medical Officer; Stargardt disease; gildeuretinol; retinal diseases; ophthalmology; clinical research; biopharmaceutical leadership